Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong · Delayed Price · Currency is HKD 5.19
+0.19 (3.80%)
Jul 10, 2026, 4:08 PM HKT
Sino Biopharmaceutical Stock Forecast
Stock Price Forecast
According to 21 analysts polled by S&P Global, Sino Biopharmaceutical stock has a consensus rating of "Strong Buy" and an average price target of $8.59. The average 1-year stock price forecast is 65.51% higher than the current stock price, while the lowest is $6.19 (+19.27%) and the highest is $10.55 (+103.28%).
Price Target: $8.59 (+65.51%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Sino Biopharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 18 | 17 | 17 | 17 | 16 |
| Buy | 5 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 22 | 21 | 22 | 22 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst UBS No rating | UBS | Buy Maintains $11.00 | Buy | Maintains | $11.00 | +111.95% | Jun 30, 2026 |
Unknown Analyst Citic Securities No rating | Citic Securities | Buy Maintains $9.00 | Buy | Maintains | $9.00 | +73.41% | Jun 27, 2026 |
| DBS | DBS | Buy Initiates $6.50 | Buy | Initiates | $6.50 | +25.24% | May 20, 2026 |
| Jefferies | Jefferies | Buy Maintains $7.00 | Buy | Maintains | $7.00 | +34.87% | Mar 31, 2026 |
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $8.50 → $7.70 | Buy | Maintains | $8.50 → $7.70 | +48.36% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
36.21B
from 31.83B
Increased by 13.74%
Revenue Next Year
39.24B
from 36.21B
Increased by 8.37%
EPS This Year
0.24
from 0.25
Decreased by -3.75%
EPS Next Year
0.26
from 0.24
Increased by 7.56%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 37.8B | ||
| Avg | 36.2B | ||
| Low | 35.3B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 18.7% | ||
| Avg | 13.7% | ||
| Low | 10.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 0.29 | ||
| Avg | 0.24 | ||
| Low | 0.22 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 13.4% | ||
| Avg | -3.7% | ||
| Low | -14.5% |